Baqiyatallah University of Medical Sciences Journal of Applied Biotechnology Reports 2322-1186 9 1 2022 03 01 Immunoinformatics Approach for Glycoprotein B-based Vaccine Candidate Design Against Infectious Laryngotracheitis Virus 484 493 145903 10.30491/jabr.2021.254153.1302 EN Samireh Faramarzi Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran 0000-0002-5523-1995 Shahla Shahsavandi Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran 0000-0002-9599-6722 Mohammad Majid Ebrahimi Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran 0000-0002-9829-0637 Journal Article 2020 10 24 Introduction: Infectious Laryngotracheitis Virus (ILTV) poses a highly contagious upper respiratory tract illness and is regarded as a major concern for the poultry industry worldwide. Considering the emergence of novel virulent variants of ILTVs, the development of novel vaccines is needed to control the disease. This study was carried out based on immunoinformatics and vaccinology strategies to introduce an effective ILTV vaccine candidate targeting glycoprotein B (gB). Materials and Methods: Both T-cell and B-cell epitopes of the gB protein with the potential to induce immune responses were identified. The highly antigenic and immunogenic PH-1 domain was selected as the potential vaccine candidate. The physiochemical properties and tertiary structure model of the domain were predicted, refined, and validated. The resulting high‐quality model was applied for docking analyses with toll‐like receptor 2. The affinity of the vaccine candidate to bind with the immune receptor and generate the appropriate immune responses was calculated based on the free energy level. Results: The results indicated the PH-1 domain of ILTV gB protein to be immunogenic and was effective in stimulating the T helper, T cytotoxic, and B cells. The domain showed high-affinity binding and stability with the TLR2 immune receptor. Conclusions: Collectively, this research provides an immunogenic candidate for designing a protein-based vaccine against ILTV. The efficacy of the construct should be examined in lab settings and in animal models.

https://www.biotechrep.ir/article_145903_1d3d2d1b7d5e20906a0283d5bfc61254.pdf